Recently, a clinical trial performed by Cancer and Leukemia Group B demonstrated that Cox-2 expression was a significant prognostic factor among patients with advanced NSCLC receiving chemotherapy [12]. This evidence concerns the gene PTGS2 and non-small cell lung carcinoma.